FinTrust Capital Advisors’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

FinTrust Capital Advisors’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-100,780	Closed	-$230K	–	1455
2024 Q2	$230K	Hold	100,780	–	–	0.04%	271
2024 Q1	$435K	Hold	100,780	–	–	0.08%	181
2023 Q4	$307K	Buy	100,780 +100,715	+154,946%	+$189K	0.06%	221
2023 Q3	$94	Hold	65	–	–	﹤0.01%	1211
2023 Q2	$353	Hold	65	–	–	﹤0.01%	1158
2023 Q1	$353	Hold	65	–	–	﹤0.01%	1147
2022 Q4	$353	Hold	65	–	–	﹤0.01%	1144
2022 Q3	$1K	Hold	65	–	–	﹤0.01%	1207
2022 Q2	$1K	Hold	65	–	–	﹤0.01%	1192
2022 Q1	$0	Hold	65	–	–	﹤0.01%	1311
2021 Q4	$1K	Hold	65	–	–	﹤0.01%	1165
2021 Q3	$1K	Hold	65	–	–	﹤0.01%	1146
2021 Q2	$1K	Hold	65	–	–	﹤0.01%	1156
2021 Q1	$2K	Buy	+65	New	+$1.51K	﹤0.01%	1113

FinTrust Capital Advisors's GTHX Position: Q3 2024 in Review

FinTrust Capital Advisors sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 100,780 shares — an estimated $230K sold.

FinTrust Capital Advisors first reported a position in GTHX in Q1 2021 and held it in 14 quarters. The position peaked at $435K in Q1 2024. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.

FinTrust Capital Advisors reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
FinTrust Capital Advisors sold 100,780 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $230K.
FinTrust Capital Advisors first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2021 and held it in 14 quarters.
FinTrust Capital Advisors's G1 Therapeutics, Inc. Common Stock position peaked at $435K in Q1 2024.
0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.

Based on FinTrust Capital Advisors's 13F filing for Q3 2024, filed 11 Oct 2024.